Cambridge Healthtech Institute’s 2nd Annual
Oligonucleotide CMC and Regulatory Strategies
Accelerating Product Development and Commercial Success
March 17-18, 2020
CHI is delighted to build on the success of last year’s inaugural Oligonucleotide CMC and Regulatory Strategies to complement our Discovery and Delivery conference. We bring together top scientists and executives from leading biotech and large pharma
to share exclusive insights on CMC, manufacturing, analytical and regulatory advancements. Learn how to optimise your product development processes and speed up time to market.
Final Agenda
Day 1 | Day 2 | Download Brochure
MONDAY, MARCH 16
12:30 - 6:30 pm Short Course and Pre-Conference Registration*
3:00 - 6:00 SC1: Circular RNAs as a New Therapeutic Modality
Instructors:
Samie Jaffrey, MD, PhD, Department of Pharmacology, Weill Medical College, Cornell University
Bojan Losic, PhD, Associate Professor, Department of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai
Additional Instructors to be Announced
6:30 - 9:30 SC2: Examining the Safety and Toxicity of Nucleic Acid Therapeutics
Instructors to be Announced
*Separate registration required. See page 3 for details.
TUESDAY, MARCH 17
7:00 am Registration and Morning Coffee
8:00 Welcome Remarks from Conference Director
Gemma Smith, Senior Conference Director, Cambridge Healthtech Institute
8:10 Chairperson’s Opening Remarks
Dmitry Samarsky, PhD, CTO, Sirnaomics
8:15 Recent Advances with Antisense Technology at Ionis Pharmaceuticals
Brett Monia, PhD, CEO, Ionis Pharmaceuticals
The development of antisense technology as a novel drug discovery platform to treat a broad range of rare and common diseases is now validated. Antisense medicines offer tremendous hope for patients afflicted with serious diseases that cannot be
addressed with traditional drug discovery platforms. With numerous antisense medicines recently receiving market authorization along with a large and diverse pipeline of medicines on the horizon, antisense is poised to revolutionize the practice
of medicine for generations.
8:45 Increasing Gene Expression at Stoke Therapeutics
Edward Kaye, MD, CEO, Stoke Therapeutics
9:15 FIRESIDE CHAT
Moderator: Dmitry Samarsky, PhD, CTO, Sirnaomics
Panelists: Brett Monia, PhD, CEO, Ionis Pharmaceuticals
Edward Kaye, MD, CEO, Stoke Therapeutics
10:00 Coffee Break in the Exhibit Hall with Poster Viewing
10:45 Chairperson’s Opening Remarks
Marc LeMaitre, PhD, Consultant, Sirnaomics
10:50 FEATURED PRESENTATION: Reinventing Oligonucleotide Synthesis
Phil Baran, PhD, Professor, Department of Chemistry, Scripps Research
The advent of phosphoramidite-based coupling chemistry and solid-phase organic synthesis democratized oligonucleotide synthesis for the biochemistry community thus paving the way for stunning developments in the field. This talk will present a fundamentally
different approach to constructing oligonucleotides containing P(S)2, chiral P(S)O and P(Me)O, and canonical P(O)2 linkages to create chimeric sequences that would be outside the realm of what can be obtained with current methods.
11:20 FEATURED PRESENTATION: Manufacturing Process and Control Strategy for GalNAc Conjugated siRNAs
Roumen Radinov, PhD, Director Process Chemistry, Alnylam Pharmaceuticals
Several GalNAc conjugated siRNAs are currently at different stages of clinical development for various programs at Alnylam. The presentation will describe the Alnylam manufacturing process for this type of compounds as well as the development of the CMC
control strategy from early stage to NDA. The possibility of using a platform approach to enhance this strategy will also be discussed.
11:50 Learnings from Process Validation of a Full-Scale Oligonucleotide Manufacturing Process
Jesse Faber, Senior Process Engineer III, ASO Process Engineering and Manufacturing, Biogen
In 2016, Biogen began construction of its first ASO manufacturing facility. After the successful manufacture of several clinical oligonucleotides, Biogen has just completed its first process validation of a commercial oligonucleotide in 2019. This presentation
will focus on key learnings from the process validation effort including process characterization, risk assessment, and platform strategies.
12:20 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
12:50 Session Break
2:00 Monte Carlo Simulations of Amidite Starting Material Impurity Incorporations for Drug Substance Specification Justifications
Francis Ring, Assistant Director, Manufacturing and Operations, Ionis Pharmaceuticals
For starting material-related product impurities, Ionis supplemented the product impurity data with Monte Carlo simulations of the corresponding starting material impurity. By building the Monte Carlo simulations from the entire amidite production history,
significantly more historical variability was captured than any individual Ionis product experienced. The methodology for building the starting material impurity and product incorporation models will be discussed along with the Monte Carlo simulation
results.
2:30 Talk Title to be Announced
Speaker to be Announced
3:00 Sponsored Presentation (Opportunity Available)
3:30 Refreshment Break in the Exhibit Hall with Poster Viewing
4:15 CMC Case Study from ProQR Therapeutics
Vera Brinks, PhD, Director Pharmaceutics, ProQR Therapeutics
4:45 Oligonucleotides: Bioanalytical and DMPK Perspective Lessons Learned
Mary M. Sherman, PhD, Principal Consultant, Preclinical & Regulatory Consulting
Having worked with several small biotechs, focused on oligonucleotide research, I have seen a pattern emerging regarding their knowledge, their questions, their strategies, and the outcomes. A summary of some of those lessons will be presented during
this presentation.
5:15 Welcome Reception in the Exhibit Hall with Poster Viewing
6:15 Dinner Short Course Registration*
6:30 - 9:30 SC3: Oligonucleotides for Cancer Immunotherapy
Instructors:
Shanthi Ganesh, PhD, Associate Director, Preclinical Oncology, Dicerna Pharmaceuticals, Inc.
Weston Daniel, PhD, Senior Director Program Management, Exicure, Inc.
Additional Instructors to be Announced
*Separate registration required.
Day 1 | Day 2 | Download Brochure
WEDNESDAY, MARCH 18
8:00 am Breakfast Breakout Roundtable Discussions
9:15 Chairperson’s Remarks
Paul Manley, President & Principal Consultant, Orvieto Consulting
9:20 Phase Appropriate Analytical Control Strategy for Antisense Oligonucleotides
Hong Jiang, Scientist II, Analytical Development, Biogen
With the commercial success of Antisense oligonucleotides (ASO) drugs, the footprint of this class of new and exciting therapeutics is quickly increasing in the clinical space. It is vitally important to develop a phase appropriate analytical control
strategy to ensure the safety and efficacy of the product while keeping the drug accessible to patients. Challenges and considerations in developing such a phase appropriate strategy will be discussed. Examples of development and implementation of
new technology and methods will be provided.
9:50 Industry Case Study from Quark Pharmaceuticals
Vidhya Gopalakrishnan, PhD, Senior Vice President, Pharmaceutical Development, Quark Pharmaceuticals
10:20 FEATURED PRESENTATION: Regulatory CMC Experience with Alnylam’s First GalNAc Conjugate
Melissa Marschel, Director, Regulatory Affairs CMC, Alnylam Pharmaceuticals
Alnylam will provide an overview of our CMC-related experiences obtaining approval for Givlaari, our first siRNA GalNAc conjugate. We will discuss the overall dossier strategy, key CMC-related challenges and key regulatory questions received.
10:50 Coffee Break in the Exhibit Hall with Poster Viewing
11:35 Practical, Quality and Regulatory CMC Considerations to Manufacture Clinical Trial Materials for Early Phase. What do you really need to do?
Kevin Fettes, PhD, Consultant and Founder, FTS Pharma Consulting
The complexity of oligonucleotide drug candidates being selected for clinical development has increased in recent years. These oligonucleotides often have significant chemical modifications requiring novel starting materials as well as technical innovations
in process development, analytical chemistry, manufacturing and controls. This places extraordinary demands on both sponsor companies and contract manufacturing organizations to meet regulatory expectations under aggressive timelines.
12:05 pm Submitting Your First Investigational New Drug (IND) Application: A Roadmap of Key Activities
Paul Manley, President & Principal Consultant, Orvieto Consulting
An IND application can be daunting for a small company making such a submission for the first time. This presentation will discuss key activities to consider as you plan for this important FDA interaction, including: Pre-IND dialogue, project plans, use
of internal and external resources, creation of your electronic submission and the IND review process.
12:35 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
1:05 Dessert Break in the Exhibit Hall with Poster Viewing
1:50 Rare Disease: CMC Regulatory Pathway
Kimberly Tyndall, Principal, CMC Tyndall Consultant
This talk will focus on CMC regulatory hurdles and pathways encountered when filing oligonucleotide drug substance and drug product. We will explore both hurdles that may be faced in the US as well as across the globe. How these can be overcome and how
to streamline the process so as to ensure quality.
2:20 PANEL DISCUSSION: How to Successfully Prepare for a Regulatory Submission and Overcome Common Hurdles
Moderator: Kimberly Tyndall, Principal, CMC Tyndall Consultant
Panelists: Steven Kates, PhD, Vice President, Regulatory Affairs, Dicerna Pharmaceuticals
Melissa Marschel, Director, Regulatory Affairs CMC, Alnylam Pharmaceuticals
Paul Manley, President & Principal Consultant, Orvieto Consulting
Mary M. Sherman, PhD, Principal Consultant, Preclinical & Regulatory Consulting
- Challenges: Manufacturing development history for regulatory filings
- Global dossiers: FDA, EMA, Japan, Brazil and Canada
- Stability data: What was permitted and what was not?
3:05 Networking Refreshment Break
3:35 Chairperson’s Remarks
Chairperson to be Announced
3:40 Biological Activity of Thiomorpholino Oligonucleotides
Marvin
Caruthers, PhD, Distinguished Professor, University of Colorado
Thiomorpholino oligonucleotides are analogues containing morpholino- and 2’deoxyribonucleosides joined through thiophosphor internucleotide linkages. These analogues stimulate biological activity in a dual luciferase assay, in exon skipping with
Marfan Syndrome and Duschenne Muscular Dystrophy, and in regulating TUG 1 RNA. Current research includes regulating microRNA maturation, editing transcription termination, exon skipping of additional genetic diseases, and antisense experiments with
RNase H.
4:10 GIVLAARITM: Story of the First-Ever Approved GalNAc Conjugated siRNA, for Acute Hepatic Porphyria
Amy
Simon, MD, Executive Director, Clinical Research, Alnylam Pharmaceuticals
4:40 Close of Oligonucleotide CMC and Regulatory Strategies
4:40 Dinner Short Course Registration*
5:00 - 8:00 SC4: Gene Editing for Targeted Therapies
Instructors:
Clifford Steer, MD, Professor of Medicine and Genetics, Cell Biology, and Development; Director, Molecular Gastroenterology Program, University of Minnesota Medical School
Khalid Shah, MS, PhD, Director, Center for Stem Cell Therapies and Imaging, Harvard Medical School; Vice Chair of Research, Brigham and Women’s Hospital
Additional Instructors to be Announced
*Separate registration required.
Day 1 | Day 2 | Download Brochure